Prime Capital Investment Advisors LLC Reduces Stock Position in HCA Healthcare, Inc. $HCA

Key Points

• Prime Capital Investment Advisors LLC reduced its stake in HCA Healthcare by 33.9%, ending up with 1,693 shares valued at $648,000 after selling 870 shares in the second quarter.
• HCA Healthcare's latest quarterly earnings surpassed expectations, reporting $6.84 EPS, compared to analysts' estimates of $6.20, and achieving revenue of $18.61 billion.
• The company has announced a quarterly dividend of $0.72 per share, with a dividend yield of 0.7% and a payout ratio of 12.11%.

Prime Capital Investment Advisors LLC lowered its stake in shares of HCA Healthcare, Inc. (NYSE:HCA - Free Report) by 33.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,693 shares of the company's stock after selling 870 shares during the period. Prime Capital Investment Advisors LLC's holdings in HCA Healthcare were worth $648,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in HCA. Cheviot Value Management LLC purchased a new stake in HCA Healthcare during the first quarter valued at about $26,000. Saudi Central Bank bought a new position in shares of HCA Healthcare during the first quarter valued at about $26,000. WPG Advisers LLC bought a new stake in shares of HCA Healthcare in the first quarter worth about $27,000. Ameriflex Group Inc. bought a new stake in shares of HCA Healthcare in the second quarter worth about $27,000. Finally, Chung Wu Investment Group LLC bought a new stake in HCA Healthcare during the 2nd quarter valued at approximately $27,000. Hedge funds and other institutional investors own 62.73% of the company's stock.

Insider Activity

In other news, EVP Michael S. Cuffe sold 3,836 shares of the stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $418.84, for a total transaction of $1,606,670.24. Following the transaction, the executive vice president directly owned 31,503 shares in the company, valued at approximately $13,194,716.52. This trade represents a 10.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.30% of the company's stock.

HCA Healthcare Trading Down 1.9%

Shares of NYSE HCA opened at $418.35 on Friday. HCA Healthcare, Inc. has a 12-month low of $289.98 and a 12-month high of $439.01. The stock has a market capitalization of $97.89 billion, a price-to-earnings ratio of 17.59, a P/E/G ratio of 1.34 and a beta of 1.40. The firm's 50-day moving average price is $403.96 and its 200-day moving average price is $375.04.

HCA Healthcare (NYSE:HCA - Get Free Report) last posted its quarterly earnings data on Friday, July 25th. The company reported $6.84 earnings per share for the quarter, topping analysts' consensus estimates of $6.20 by $0.64. HCA Healthcare had a net margin of 8.21% and a negative return on equity of 7,363.11%. The company had revenue of $18.61 billion for the quarter, compared to analyst estimates of $18.49 billion. During the same period in the prior year, the company posted $5.50 EPS. The firm's revenue for the quarter was up 6.4% on a year-over-year basis. HCA Healthcare has set its FY 2025 guidance at 25.500-27.000 EPS. On average, equities analysts predict that HCA Healthcare, Inc. will post 24.98 EPS for the current fiscal year.

HCA Healthcare Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Tuesday, September 16th were paid a dividend of $0.72 per share. The ex-dividend date was Tuesday, September 16th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.7%. HCA Healthcare's dividend payout ratio (DPR) is currently 12.11%.

Analyst Ratings Changes

Several research firms have weighed in on HCA. Wolfe Research cut HCA Healthcare from an "outperform" rating to a "peer perform" rating in a research report on Monday, July 28th. KeyCorp boosted their price objective on shares of HCA Healthcare from $370.00 to $465.00 and gave the stock an "overweight" rating in a report on Wednesday. Morgan Stanley cut their target price on shares of HCA Healthcare from $410.00 to $400.00 and set an "equal weight" rating for the company in a research report on Monday, July 28th. Barclays boosted their price objective on shares of HCA Healthcare from $390.00 to $445.00 and gave the company an "overweight" rating in a research report on Thursday, September 18th. Finally, Weiss Ratings reissued a "buy (b-)" rating on shares of HCA Healthcare in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $422.31.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.

Want to see what other hedge funds are holding HCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCA Healthcare, Inc. (NYSE:HCA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.